Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Офтальмология / Английские материалы / Moorfields Manual of Ophthalmology_Jackson_2007

.pdf
Скачиваний:
0
Добавлен:
28.03.2026
Размер:
32.21 Mб
Скачать

GLAUCOMA 7 Chapter

Fig. 7.3: Goldmann tonometer with calibration bar attached showing calibration to 0, 20, and 60 mm Hg (left to right).

283

Interpreting humphrey visual field tests

Interpreting Humphrey Visual

Field Tests

Background Static, white-on-white, semi-automated perimetry is the standard method for identifying and assessing progression of functional visual loss from glaucoma.

Single field test Ask, is the field: 1. Reliable and 2. Glaucomatous?

The best measure of reliability given by the machine is the false-positive level: high levels of fixation losses and false negatives may not indicate unreliability.

Causes of artefact include inattention (producing a ‘clover-leaf’ field), small pupil size, uncorrected refractive error, lens rim, lid/brow, media opacities, and macular disease.

Characteristic sites of early glaucomatous damage are paracentral, nasal, and arcuate.

‘Raw’ thresholds give the height of the ‘hill of vision’ (in dB of attenuation: high dB values mean a dim stimulus was seen) at test locations.

Total deviation compares the patient’s ‘hill of vision’ to age-matched normals.

Pattern deviation highlights focal rather than diffuse loss (total deviation shows both).

Global indices attempt to summarize plots in a single number: MD (mean deviation) for total deviation, PSD (pattern standard deviation) for the pattern of deviation.

The Glaucoma Hemifield Test compares corresponding clusters in superior and inferior hemifields. Repeatable abnormality suggests glaucoma.

Always evaluate fields in the light of other clinical findings, especially the optic disc appearance. If in doubt, repeat.

Field series Ask if a field defect is: 1. Progressing and 2. If so, how fast?

 

Ideally, all fields in the series should be same type, e.g. all

 

Standard Full Threshold (FT) or all SITA. If the series is

 

284

mixed FT/SITA use Pattern Deviation for progression.

 

 

Some clinicians feel that clinical judgement alone is insufficient to decide about progression. Consider using glaucoma change software (Figs. 7.4, 7.5):

1. Statpac2 (recently upgraded to Glaucoma Progression Analysis) compares fields with baseline for significant change.

2. PROGRESSOR models the behaviour of each test location over time to detect significant progression.

At least five fields are needed for a reliable decision.

Sources of error include fluctuation (shortand long-term), learning effects, inappropriate change criteria, inappropriate frequency of testing, artefact (see Single field test, above), poor reliability (see Single field test, above), and field loss beyond the dynamic range of the perimeter.

Monocular field determines management. Binocular field determines quality of life.

GLAUCOMA 7 Chapter

Fig. 7.4: Statpac 2 glaucoma change probability analysis.

 

The test locations circled in blue show significant

 

deterioration in two out of the three fields shown. Those

 

circled in red showing significant deterioration in each

 

of the three consecutive fields.

285

Interpreting humphrey visual field tests

Fig. 7.5: PROGRESSOR output for the same visual field series shown in Fig. 7.4. The left pane shows the cumulative graphical output with each test location represented by a bar graph in which the length of the bar relates to the depth of the defect, and the colour representing the probability value of the regression slope. The right pane shows the test locations that satisfy progression criteria. Note that the pattern of progressing points is similar to the circled points in Fig. 7.4.

286

Primary Open Angle Glaucoma

Background A progressive optic neuropathy associated with distinctive, excavated disc appearance and a pattern of visual field loss localizing damage to the optic nerve head. Usually bilateral, but often asymmetric. Affects 2% of people over 40 years of age. Risk factors include Black African or Caribbean origin, positive family history, myopia, and increasing age. Elevated IOP is the most important modifiable risk factor for development of primary open angle glaucoma (POAG).

Symptoms Typically asymptomatic until advanced visual field loss occurs.

History Ask specifically for a family history of glaucoma and glaucoma blindness. Exclude causes of secondary glaucoma (history of trauma, uveitis, or steroid usage).

Examination

Slit lamp : the anterior segment is normal in POAG. Exclude signs of secondary glaucoma, e.g. pigment dispersion, pseudoexfoliation, neovascularization, anterior segment dysgenesis, angle closure and aphakia. The risk of POAG increases with the level of IOP.

Gonioscopy : by definition the angle is open, not occludable, and with no peripheral anterior synechiae. Gonioscopy is essential to differentiate POAG from other forms of glaucoma.

Optic disc : progressive, pathological loss of neuroretinal rim and associated nerve fibre layer defects, manifesting as enlargement of the cup-to-disc ratio.

Investigations

Visual field : look for progressive field loss anatomically consistent with the area of neuroretinal rim loss. Monitor with regular automated perimetry every 3–4 months if progression is suspected.

Optic disc imaging : a baseline photograph or scanning laser ophthalmoscope image is very useful for future comparison and detection of change.

Central corneal thickness : affects measured IOP, with thick

corneas registering higher IOP (thin cornea vice versa). Mean thickness is ≈550 μm (SD, 35 μm).

GLAUCOMA 7 Chapter

287

Primary open angle glaucoma

Diagnosis Moderate/advanced POAG is easily diagnosed with typical disc and field change. Early glaucoma is more difficult and may need monitoring for months or years before progression confirms the diagnosis.

Differential diagnosis

Ocular hypertension : IOP >21 mmHg but no glaucomatous optic neuropathy.

Normal pressure glaucoma (NPG): IOP <21 mmHg with characteristic progressive glaucomatous optic neuropathy. Identifying NPG as a subset of POAG is controversial as the risk gradually increases through the range of IOP.

Treatment All current treatments principally aim to lower IOP and reduce or eliminate glaucomatous progression. Options are medical, laser, or surgery.

Casualty : Only start treatment if the diagnosis is certain and IOP is >28 mmHg, or if there is advanced disc damage. Start with single therapy regardless of IOP. Topical prostaglandin analogues are used as first-line treatment. Arrange routine clinic referral.

Clinic : Treatment is tailored to the patient’s circumstances (consider age, stage of glaucoma, etc.). Aim initially for a 30% IOP reduction medically. Stop treatment if not effective and use alternatives. Avoid polypharmacy. Monitor regularly for disc and field progression. If IOP reduction is not adequate to stop progression on maximal medical therapy (two or three drops) consider laser trabeculoplasty (p. 296) or trabeculectomy surgery (p. 289). The ‘target pressure’ for an individual patient is the estimated IOP needed to prevent progression: it may be different in each eye and may vary with time and changing circumstances (Fig. 7.6).

 

 

 

 

 

 

 

 

 

 

 

 

 

Higher

 

Old

 

High

 

Early

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Target IOP

 

Age

 

Presenting IOP

 

Glaucoma

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Lower

 

Young

 

Low

 

Advanced

 

 

 

 

 

 

 

 

 

 

 

 

288 Fig. 7.6: Factors influencing the target IOP.

Trabeculectomy I:

Surgical Technique

Indications Progressive glaucomatous field and/or disc changes. Failure to achieve target IOP. Failure or inability to use regular medication.

Anaesthesia

General anaesthetic : children, anxious adults, complex/long procedures, high preoperative IOP (>30 mmHg).

Local anaesthetic : use low volumes of anaesthetics combined with hyaluronidase to prevent pressure elevations. Subconjunctival anaesthesia is feasible combined with intracameral anaesthetic.

Consent

Benefit : Stabilize but not improve vision. Reduced dependence on medication.

Risk : Blindness (‘wipe-out’ in advanced glaucoma, endophthalmitis, suprachoroidal haemorrhage), loss of one line of Snellen acuity is likely, 12–66% chance of cataract

progression at 3 years (most in first year), long-term possibility of blebitis ± endophthalmitis and need for surgical bleb revision, problems wearing contact lenses. Failure to control IOP and continued dependence on medication occurs in 10–30%.

Preoperative eyedrops

Steroids and NSAIDs : topical application 24–72 hours before surgery in patients with conjunctival hyperaemia, who require iris manipulation or if fibrinous uveitis is possible.

IOP-lowering agents : consider stopping aqueous suppressants in advance with outpatient IOP monitoring.

Technique See Box 7.1.

GLAUCOMA 7 Chapter

289

Trabeculectomy I: surgical technique

Box 7.1: Trabeculectomy

1.Superior limbus, under the lid, is the only acceptable site (document lid position preoperatively).

2.Place a 7/0 corneal traction suture (semicircular needle).

3.Use spring scissors to make a limbal conjunctival incision (‘fornix-based flap’), at least 10 mm long.

4.Posteriorly, dissect a 15 × 15 mm subconjunctival pocket.

5.Lift conjunctiva and separate its attachments to muscle tendon.

6.Create a 4 × 3 mm scleral pocket by lamellar dissection (50% thickness) (Fig. 7.7).

7. Cut side incisions to within 1 mm of the limbus (Fig. 7.8).

8.Soak 4–6 sponges with mitomicin C (0.2 or 0.5 mg/mL) or 5FU (50 mg/mL) if required.

9.Fold and insert sponges into the subconjunctival and scleral pockets. Treat as large an area as possible but avoid the conjunctival wound edges (Fig. 7.9). After 3 minutes remove sponges and irrigate with 20 mL of balanced saline solution (BSS).

10.Preplace 10/0 Nylon sutures on the posterior corners of the scleral flap.

11.Make an oblique paracentesis. Consider continuous anterior chamber infusion in ‘high-risk’ patients.

12.Create a small (1 mm) limbal keratectomy with punch, or blade and scissors under the scleral flap (Fig. 7.10).

13.Create a peripheral iridectomy.

14.Suture the flap watertight with a combination of permanent, releasable or adjustable sutures (especially important with MMC use) (Fig. 7.11).

15.Test outflow by injecting BSS into the paracentesis, before conjunctival closure. Rotate any ‘permanent’ scleral flap sutures.

16.Close conjunctiva with 10/0 Vicryl purse-string sutures at the corners, and mattress sutures through conjunctiva and limbus.

17.Inject subconjunctival steroid and antibiotic, 180º away from the trabeculectomy site.

18.Ensure careful postoperative management. (see p. 294)

290

A B

C D

Fig. 7.7: Scleral flap design. Long, narrow, and triangular flaps (A, B, C) encourage aqueous flow laterally towards the limbus, increasing the risk of conjunctival thinning. A short, broad flap (D) is preferred, as it directs aqueous flow posteriorly, away from the limbal conjunctiva.

GLAUCOMA 7 Chapter

Fig. 7.8: Scleral flap. Limited side cuts help prevent ‘aqueous

 

jets’ at the limbus which can produce conjunctival thinning.

291

Trabeculectomy I: surgical technique

Fig. 7.9: Mitomycin-soaked sponge being inserted under the conjunctiva while protecting the conjunctival edge with a clamp.

Fig. 7.10: Small sclerostomy with iris presenting prior to iridectomy. Note preplaced Nylon sutures.

292